ClinicalTrials.gg
CompletedNCT03650491Updated Jul 27, 2022

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 1 interventional study of FOR46 in Multiple Myeloma, Multiple Myeloma in Relapse and Multiple Myeloma With Failed Remission, sponsored by Fortis Therapeutics, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-27.

Sponsored by Fortis Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2022, 4 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 2,168 studies in Multiple Myeloma with a site in United States — 273 open to participants now, 501 under way, 66 of them phase 3. Multiple Myeloma · United States.

Enrollment
1,057th of 1,901
31 · median 36
Started
2019
with 84 others
Phase 1
559 of 2,168
64 open now
Registered
1,486th of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 1,057th largest by enrollment of the 1,901 interventional ones that give a count, is one of 85 that started in 2019, is one of 559 in phase 1, and was the 1,486th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

273 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

268 more — sign in →

All 273 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

This study will test the safety and efficacy of FOR46 given every 21 days to patients with relapsed or refractory multiple myeloma.

The name of the study drug involved in this study is: FOR46 for Injection

Read the detailed description

This study is designed to evaluate the safety, tolerability and antitumor activity of FOR46 in patients with relapsed or refractory multiple myeloma. This study will be conducted in two parts:

Dose escalation:

This part will evaluate increasing doses of FOR46 to identify the maximum tolerated dose (MTD). The first patient enrolled on the study will receive the lowest dose of FOR46. Once this dose is shown to be safe, a second patient will be enrolled at the next higher dose. Patients will continue to be enrolled into either single or multiple patient groups receiving increasing doses until the MTD is reached.

Dose expansion:

This part of the study will further evaluate the safety, tolerability and antitumor activity of FOR46 at a dose shown to be safe in the dose escalation part of the study.

03

Conditions studied

  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Multiple Myeloma With Failed Remission

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 18 years of age
  • Measurable MM that is to established therapies with known clinical benefit in RRMM or intolerant of those established MM therapies. must include a proteasome inhibitor (PI), an immunomodulatory imide drug (IMiD) and a CD38-directed therapy in any order of combination.
  • performance status of 0 or 1
  • Adequate hematologic, renal and hepatic function
  • Females of must have a negative serum pregnancy test and use a medically acceptable form of
  • Male patients with with female partners of childbearing potential must agree to use 2 effective methods of contraception
  • Patients must provide signed

Exclusion criteria

Exclusion Criteria:

  • Persistent toxicities from previous anticancer therapy
  • Grade ≥ 2 peripheral neuropathy from any etiology or has a genetic disorder that is associated with peripheral neuropathy even without current neuropathic manifestations
  • Has received treatment with a stem cell transplant within 12 weeks before administration of patient's first dose of FOR46
  • Has had radiation or systemic anticancer therapy within 14 days before first dose of FOR46
  • Has received treatment with an drug within 28 days before first dose of FOR46
  • Has had a major surgical procedure within 28 days before administration of the patient's first FOR46 dose
  • Is breastfeeding
  • Clinically significant cardiovascular disease
  • Uncontrolled, clinically significant pulmonary disease
  • Uncontrolled intercurrent illness
  • Has known positive status for or either active/chronic /C
  • Requires anticoagulation with warfarin or direct thrombin inhibitor; a of 7 days before the administration of a patient's first FOR46 dose is required for patients removed from these treatments
  • Requires medications that are strong inhibitors or strong inducers of
  • Has a history of episodic atrial fibrillation or flutter; patients with chronic atrial fibrillation are not excluded.
  • Prior treatment with an ADC containing Monomethyl auristatin E (MMAE) or Monomethyl auristatin F (MMAF).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Experimental: FOR46 (Dose Escalation)

    Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.

    Drug: FOR46

  • Experimental
    Experimental: FOR46 (Dose Expansion)

    Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.

    Drug: FOR46

Interventions

  • DrugFOR46

    FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Number of patients with treatment-related adverse events as assessed by NCI CTCAE v5.0.

    Time frame: Through 1 month following last dose

  2. Occurrence of dose-limiting toxicities

    The severity and incidence of dose-limiting toxicities related to escalating dose levels of FOR46

    Time frame: Through 1 month following last dose

  3. Disease response

    Overall response rate of FOR46, defined as all responses greater than or equal to a partial response, complete response, stringent complete response, or minimal residual disease negativity

    Time frame: 6 months

Secondary outcomes

  1. Characterize FOR46 plasma concentration

    FOR46 maximum plasma concentration

    Time frame: Through 1 month following last dose

  2. Characterize the FOR46 area under the curve

    FOR46 area under the plasma concentration-time curve

    Time frame: Through 1 month following last dose

  3. Characterize FOR46 elimination

    FOR46 elimination half-life

    Time frame: Through 1 month following last dose

  4. Antidrug Antibodies

    Change from baseline in serum levels of antidrug antibodies

    Time frame: Through 1 month following last dose

  5. Duration of response

    Assessed by IMWG criteria

    Time frame: From first dose through 6 months following last dose

  6. Progression-free survival

    Assessed by IMWG criteria

    Time frame: From first dose through 6 months following last dose

  7. Time to progression

    Assessed by IMWG criteria

    Time frame: From first dose through 6 months following last dose

07

Study locations

7 sites
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94143, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
    Baltimore, Maryland 21231, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Washington University in St. Louis-Siteman Cancer Center
    Saint Louis, Missouri 63310, United States
  • Icahn School of Medicine at Mt. Sinai
    New York, New York 10029, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Jan 2022, 33 months.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 33 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2018
First posted
Aug 28, 2018
StartActual
Apr 3, 2019
Primary completionActual
Jan 31, 2022
CompletionActual
Jan 31, 2022
Last update
Jul 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03650491
Lead sponsor
Fortis Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 28, 2018
Start date
Apr 3, 2019
Primary completion
Jan 31, 2022
Completion
Jan 31, 2022
Last update
Jul 27, 2022

Study contacts

Andrew Dorr, MD
study director · Fortis Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD46 Antibody-drug Conjugate FOR46

Start the discussion